Difference between revisions of "Estramustine (Emcyt)"
m |
m (→References) |
||
Line 24: | Line 24: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
+ | [[Category:Oral chemotherapy]] | ||
+ | |||
[[Category:Nitrogen mustards]] | [[Category:Nitrogen mustards]] | ||
+ | |||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:Drugs FDA approved in 1981]] | [[Category:Drugs FDA approved in 1981]] |
Revision as of 21:33, 25 November 2014
General information
Class/mechanism: Nornitrogen mustard (similar to mechlorethamine) linked to estradiol. The estradiol component helps the drug to be preferentially delivered to estrogen receptor-positive cells. The mustard component serves as an alkylator and causes DNA crosslinks. Treatment may result in elevated plasma levels of estradiol.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Estramustine (Emcyt) patient drug information (Chemocare)[3]
- Estramustine (Emcyt) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/24/1981: Initial FDA approval
Also known as
Estracit